NewsPronto

 
Times Advertising


.

PR Newswire

Tavneos® (avacopan) approved in Australia for the treatment of ANCA-associated vasculitis

  • Written by PR Newswire Asia - News Pronto RSS
imageimage

First targeted therapy available for the treatment of two main types of ANCA-associated vasculitis (AAV), a rare and systemic disease

MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced the Therapeutic Goods Administration (TGA) in Australia has approved Tavneos® in...

Read more: Tavneos® (avacopan) approved in Australia for the treatment of ANCA-associated vasculitis

More Articles ...

  1. Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb
  2. Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
  3. Dombbit launches Self-Recharged Crypto Miner
  4. No easy way to communicate risks of climate change, new research finds
  5. Atlantic Nickel announces another record financial and operational performance in 2022